Security
bioAffinity Technologies, Inc. Warrant · BIAFW
BIAFWNASDAQWarrantCurrentCIK 1712762Updated Oct 14, 2026
Name history
bioAffinity Technologies, Inc. · through Oct 13, 2026
BIAFW price & chart
Loading TradingView…
NASDAQ:BIAFW on TradingView ↗About the company
bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung, is a non-invasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
In the news
No coverage from other publishers is available.
Seeking Alpha
bioAffinity Technologies, Inc. (BIAF) Discusses Noninvasive Testing and Risk Stratification for Indeterminate Lung Nodules Transcript ↗
bioAffinity Technologies, Inc. (BIAF) Discusses Clinical Integration of CyPath Lung in Pulmonary Nodule Assessment and Early Lung Cancer Diagnosis Transcript ↗
Recent filings
Other Events
Items 8.01, 9.01
PRER14A filing
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Other Events
Items 1.01, 3.02, 8.01, 9.01
424B5 filing
424B5 filing
Show 5 more recent filings
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
PRE 14A filing
Other Events
Items 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 10,960,772Source | 6,513,667Source | 8,221,552Source | 12,182,125Source |
| Property, Plant and Equipment, NetUSD | 265,593Source | 375,385Source | 458,633Source | 214,438Source |
| GoodwillUSD | 1,404,486Source | 1,404,486Source | 1,404,486Source | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 716,806Source | 775,139Source | 833,472Source | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 6,449,782Source | 1,105,291Source | 2,821,570Source | 11,413,759Source |
| Inventory, NetUSD | 53,548Source | 27,608Source | 18,484Source | 5,540Source |
| Assets, CurrentUSD | 7,565,208Source | 2,695,098Source | 3,972,745Source | 11,961,687Source |
| Prepaid Expense and Other Assets, CurrentUSD | 519,916Source | 422,995Source | 321,017Source | 531,899Source |
| Operating Lease, Right-of-Use AssetUSD | 334,289Source | 463,011Source | 370,312Source | — |
| Other Assets, NoncurrentUSD | 12,815Source | 19,676Source | 16,060Source | 6,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 3,683,116Source | 3,911,631Source | 3,366,297Source | 1,138,682Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 1Source | — | — | — |
| Common Stock, Value, IssuedUSD | 31,461Source | 106,593Source | 65,762Source | 58,669Source |
| Additional Paid in CapitalUSD | 75,800,258Source | 56,139,753Source | 49,393,972Source | 47,652,242Source |
| Retained Earnings (Accumulated Deficit)USD | -68,554,064Source | -53,644,310Source | -44,604,479Source | -36,667,468Source |
| Stockholders' Equity Attributable to ParentUSD | 7,277,656Source | 2,602,036Source | 4,855,255Source | 11,043,443Source |
| Liabilities and EquityUSD | 10,960,772Source | 6,513,667Source | 8,221,552Source | 12,182,125Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,906,166Source | 3,104,905Source | 2,247,829Source | 1,138,682Source |
| Operating Lease, Liability, CurrentUSD | 139,220Source | 127,498Source | 94,708Source | — |
| Accounts Payable, CurrentUSD | 761,901Source | 987,311Source | 604,789Source | 345,042Source |
| Operating Lease, Liability, NoncurrentUSD | 202,878Source | 342,098Source | 283,001Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,717,989Source | 1,398,722Source | 1,149,811Source | 541,894Source |
| Deferred Revenue, CurrentUSD | 42,405Source | 24,404Source | 33,058Source | — |
| Deferred Tax Liabilities, NetUSD | 184,998Source | 311,678Source | 137,014Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | 8,600,000Source | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 671,474Source | 989,681Source | 748,823Source | 248,592Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | 25,940Source | 9,124Source | 12,944Source | 5,540Source |
| Increase (Decrease) in Accounts PayableUSD | -225,410Source | 382,521Source | -14,501Source | 114,635Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -9,328,842Source | -7,264,795Source | -6,037,806Source | -4,070,845Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | 2,186,497Source | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -60,568Source | -79,083Source | -2,209,399Source | -219,987Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 60,568Source | 79,083Source | 22,902Source | 219,987Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 14,733,901Source | 5,627,599Source | -344,984Source | 14,343,953Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 5,344,491Source | -1,716,279Source | -8,592,189Source | 10,053,121Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 44,042Source | 17,610Source | 37,125Source | 30,637Source |
| Income Taxes Paid, NetUSD | 23,385Source | 11,650Source | 20,993Source | 2,459Source |
| Additional Financial Items | ||||
| Accretion ExpenseUSD | — | — | — | 2,055,627Source |
| Share-based Payment Arrangement, ExpenseUSD | 671,474Source | 989,681Source | 748,823Source | 248,592,000Source |
| Amortization of Intangible AssetsUSD | 58,334Source | 58,333Source | 16,528Source | — |
| DepreciationUSD | 170,359Source | 162,332Source | 233,064Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | 212,258Source |
| GoodwillUSD | 1,404,486Source | 1,404,486Source | 1,404,486Source | — |
| Income Tax Expense (Benefit)USD | 44,042Source | 11,650Source | 20,993Source | 2,459Source |
| InterestExpenseNonoperatingUSD | 44,372Source | 92,475Source | — | — |
| Investment Income, InterestUSD | 23,385Source | 17,610Source | 122,131Source | 46,708Source |
| Net Income (Loss) Attributable to ParentUSD | -14,909,754Source | -9,039,831Source | -7,937,011Source | -8,154,113Source |
| Nonoperating Income (Expense)USD | -4,293,204Source | -74,736Source | 57,210Source | — |
| Operating ExpensesUSD | 16,734,467Source | 18,315,467Source | 10,505,727Source | 4,015,394Source |
| Proceeds from Stock Options ExercisedUSD | — | 74,899Source | — | 74,900Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 6,161,959Source | 9,362,022Source | — | 4,803Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 9,913,729Source | 9,943,473Source | 6,790,654Source | 2,727,071Source |
| Operating Income (Loss)USD | -10,572,508Source | -8,953,445Source | -7,973,228Source | -4,011,058Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -14,865,712Source | -9,028,181Source | -7,916,018Source | -8,151,654Source |
| Income Tax Expense (Benefit)USD | 44,042Source | 11,650Source | 20,993Source | 2,459Source |
| Net Income (Loss) Attributable to ParentUSD | -14,909,754Source | -9,039,831Source | -7,937,011Source | -8,154,113Source |
| Earnings Per Share, BasicUSD per share | -8.66Source | -0.75Source | -0.91Source | -1.81Source |
| Earnings Per Share, DilutedUSD per share | -8.66Source | -0.75Source | -0.91Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,721,082Source | 12,125,029Source | 8,747,509Source | 4,498,964Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,721,082Source | 12,125,029Source | 8,747,509Source | — |
| Interest Expense (non-operating)USD | 44,372Source | 92,475Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 58,334Source | 58,333Source | 16,528Source | — |
| Current Income Tax Expense (Benefit)USD | 44,042Source | — | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 504,836Source | 605,637Source | 249,592Source | 10,182Source |
| Gross ProfitUSD | — | — | — | 4,336Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | 0.99Source | — |
| Interest ExpenseUSD | — | — | 37,125Source | 2,532,640Source |
| Investment Income, InterestUSD | 23,385Source | 17,610Source | 122,131Source | 46,708Source |
| Nonoperating Income (Expense)USD | -4,293,204Source | -74,736Source | 57,210Source | — |
| Operating ExpensesUSD | 16,734,467Source | 18,315,467Source | 10,505,727Source | 4,015,394Source |
| Research and Development ExpenseUSD | 1,383,359Source | 1,461,227Source | 1,467,936Source | 1,142,777Source |
Offerings
Registration 333-298597
Registration 333-296764
- Gross proceeds
- 120000.0
- Net proceeds
- 2961554.0
- Deal price
- 0.8
- Shares
- 150000
- Offering amount
- $120,000.
- Offering price
- $0.80
- Ticker
- BIAF
Underwriters: WallachBeth Capital LLC
Registration 333-295465
Registration 333-290480
- Gross proceeds
- 4798284.03
- Net proceeds
- 4414421.31
- Deal price
- 2.5
- Shares
- 1919314
- Offering price
- $2.50
- Ticker
- BIAF
Registration 333-289944
Registration 333-286921
- Gross proceeds
- 3233400.58
- Net proceeds
- 2974728.54
- Deal price
- 0.32
- Shares
- 10104377
- Offering price
- $0.32
- Ticker
- BIAF
Registration 333-286497
Filing attachments
ex99-1.htm · 8-K · 2026-10-13
Exhibit 99.1 News Release bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026 Findings report on ability to measure cellular and soluble inflammatory protein biomarkers in sputum, including biologic drug targets Company advances research and development in diagnostic tests for major lung diseases building on CyPath® Lung + AI foundation Global asthma therape…
Read attachment ↗ex4-1.htm · 8-K · 2026-10-09
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT BIOAFFINITY TECHNOLOGIES, INC. Warrant Issue Shares: Date: October 9, 2026 ────────────────────────────────────── THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “ Warrant ”) certifies that, for value received, [__] or its assigns (the “ Holder ”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “ Initial Exercise …
Read attachment ↗ex4-2.htm · 8-K · 2026-10-09
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSA…
Read attachment ↗ex4-3.htm · 8-K · 2026-10-09
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSA…
Read attachment ↗ex99-1.htm · 8-K · 2026-10-09
Exhibit 99.1 News Release bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules SAN ANTONIO, Texas (October 8, 2026) - bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it has entered into a definitive agreement with a…
Read attachment ↗ex99-2.htm · 8-K · 2026-10-09
Exhibit 99.2 News Release bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules SAN ANTONIO, Texas (October 9, 2026) - bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it has closed its previously announced registered di…
Read attachment ↗